Author

V. Velcheti

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:metabolomics· 1

Frequent Co-Authors

H. Ji· 2 shared K.-K. Wong· 2 shared Y. Xue· 2 shared A. Hata· 1 shared A. J. Aguirre· 1 shared A. L. Moriera· 1 shared A. Lopez· 1 shared A. S. Patel· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H. Ji

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 7, 2023

Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer

X. Tong, A. S. Patel, E. Kim…·H. Ji

The paper identifies adeno-to-squamous transition (AST) as a mechanism of resistance to KRAS inhibitors in LKB1 mutant lung cancer and links KRT6A expression to poor patient outcomes.

DOI 10.1101/2023.09.07.556567

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 18, 2023

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1-mutant lung cancer

J. Deng, D. H. Peng, D. Fenyo…·K.-K. Wong

The paper identifies CD38 as a therapeutic target in LKB1-mutant lung cancer through in vivo metabolomics and shows that targeting CD38 inhibits tumor growth.

DOI 10.1101/2023.04.18.537350

mousehuman

𝕏 PostBluesky